http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005016868-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d4ead977f2062fbbf75fdb54c6780001 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ebceae7ab7655dd9946b9947f66b7104 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_27a71ddaaa2f5a8c228fc6cb3f3b3098 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C2601-14 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C235-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C255-57 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C235-78 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D333-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D209-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C233-51 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D209-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C233-51 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C255-57 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D333-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C235-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C235-78 |
| filingDate | 2004-08-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fd81e088de63f2e0d19b7147fdc59f0d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7cb1bec922fe5f5cf03a6e062bd131fc |
| publicationDate | 2005-02-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2005016868-A2 |
| titleOfInvention | Matrix metalloproteinase inhibitors |
| abstract | Compounds of Formula (I), wherein R1 represents optionally substituted -C4-12 alkyl, -C2-10alkylcycloalkyl, -C2-6 alkyl heterocycloalkyl, -C2-6alkylaryl, optionally substituted 5- or 6- membered aryl or heteroaryl, except pyridinyl. Z represents a bond, CH2, O, S, SO, SO2, NR4, OCR4R5, CR4R5O, or Z, R1 and Q together form an optionally substituted fused tricyclic group; Q represents an optionally substituted 5- or 6- membered aryl or heteroaryl ring; X represents COR3; R2 represents CONH2, CO2H, CO2R7, SO2R7 or SO2NR8R9, except that R2; may not represent CO2R7 when X is CONH2 ; R3 represents OR6, or NR8R9; R4 and R5 each independently represents H, C1-6 alkyl or C1-4 alkylaryl; R6 represents H or C1-6 alkyl; R7 represents C1-6 alkyl; R8 and R9 each independently represents H or C1-6 alkyl or R8 and R9 together with the nitrogen atom to which they are attached form a 5- or 6- membered ring which may optionally include 1 or more further heteroatoms selected from O, S and N; and physiologically functional derivatives thereof with the exception of [3-(acetylamino)-4-cyclohexylphenyl]-butanedioic acid and 3-(acetylamino)-4-cyclohexylphenyl]-butanedioic acid diethyl ether; butanedioic acid [3-methoxy-4-(phenylmethoxy)phenyl]; butanedioic acid [4-(phenylmethoxy)phenyl]; with the proviso that when R1 represents C4-12 alkyl, Z is other than a bond, O or CH2; and physiologically functional derivatives thereof , processes for their preparation, pharmaceutical formulations containing them and their use as inhibitors of matrix metallproteinase enzymes (MMPs) are described. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107793415-A |
| priorityDate | 2003-08-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 496.